Serum Institute of India Pvt. Ltd Overview
Company Headquarters: Pune, Maharashtra, India
Founded: 1966
Workforce: ~ 1001-5000
Company Working: Serum Institute of India Pvt. Ltd is a major player in the global vaccines market. The company manufactures more than 1.3 billion doses per year and is the largest manufacturer in the world, by volume. It is also India’s largest biotechnology company. It is estimated that about 65% of the children in the world receive at least one vaccine manufactured by the Serum Institute. It focuses on manufacturing life-saving vaccines for chronic diseases such as Diphtheria, Tetanus, Pertussis, Hib, BCG, r-Hepatitis B, Measles, Mumps, and Rubella. It operates through business segments, namely, bacterial vaccines, polysaccharide conjugate vaccines, influenza vaccines, viral vaccines, anti-sera, uro-oncology, recombinant products, and combination vaccines. It has operations in key five continents (Africa, America, Asia, Australia/Oceania, and Europe) and provides its products in more than 170 countries. It generates maximum revenue from the sales of vaccines.
Strategy
Serum Institute of India Pvt. Ltd.’s R&D efforts are focused on developing cost-effective vaccines that meet the specific needs of different segments of the global population. It is actively involved in reducing animal suffering and the development of possible alternatives to in-vivo testing of its products. It performs pre-clinical and clinical research in compliance with Good Laboratory Practice (GLP) and Good Clinical Practice (GCP) guidelines on all its products before marketing worldwide.
